Vanda Pharma jumps after US FDA approves motion sickness drug

Vanda Pharmaceuticals

31/12/2025 10:51

** Shares of drugmaker Vanda Pharmaceuticals VNDA.O jump 19.6% to $8.41 premarket

** VNDA said late on Tuesday that the U.S. FDA has approved its drug to prevent motion-induced vomiting

** The company expects to launch the drug, Nereus, in the coming months

** Motion-induced vomiting is a response triggered by mixed signals between the eyes, inner ear and body sensors during activities such as boating, driving or flying

** As of last close, VNDA up 46.7% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))